menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Biologics gaining ground in HS, but more support needed: Spherix

    FIERCE PHARMA

    Novartis`s Biologic Cosentyx (Secukinumab) Receives Approval in US

    FDA

    Novartis` Cosentyx gets US nod for hidradenitis suppurativa

    GLOBENEWSWIRE

    Novartis` Biologic Cosentyx (secukinumab) Receives Approval in the U.S.

    FDA

    Novartis gets US nod for intravenous form of Cosentyx

    PR NEWSWIRE

    Novartis`s Cosentyx (secukinumab) Receives Approval in Europe

    EMA

    Novartis receives European approval for Cosentyx

    PRESS RELEASE

    Novartis` Biologic Cosentyx (Secukinumab) Receives Approval in the U.S.

    FDA

    Novartis targets new fields—and CAR-T—for immunology growth

    FIERCE PHARMA

    Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

    PRESS RELEASE

    Patients with hidradenitis suppurativa experienced efficacy with Cosentyx

    GLOBENEWSWIRE

    AbbVie sheds autoimmune disease drug in blow to partner Inventiva

    PHARMAPHORUM

    Novartis ties HQ raid to Cosentyx patent fight against Lilly

    FIERCEPHARMA

    Novartis Cosentyx shows improvements with hidradenitis suppurativa

    GLOBENEWSWIRE

    EU approves Norvatis’ Cosentyx for childhood arthritis

    PHARMATIMES

    Novartis Cosentyx nabs +ve CHMP opinion for expanded use in childhood arthritis

    GLOBENEWSWIRE

    Novartis` Biologic Cosentyx (Secukinumab) Receives Approval in the U.S.

    FDA

    FDA Approves Cosentyx in enthesitis-related arthritis, psoriatic arthritis

    PRNEWSWIRE

    Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials

    FIERCEBIOTECH

    Cosentyx displays a 72 percent reduced arthritis flare risk

    EUROPEANPHARMACEUTICALREVIEW

    Novartis’ Cosentyx cuts flare risk in juvenile idiopathic arthritis trial

    CLINICALTRIALSARENA

    Novartis autoinjector effective for treating psoriasis

    PHARMAFILE

    Key players in psoriasis offer strong support through branded digital channels

    BIOSPECTRUM ASIA

    NICE recommends Novartis’ Cosentyx for children with severe psoriasis

    PHARMATIMES

    NICE approves secukinumab for young people with severe plaque psoriasis

    PHARMA FILE

    Kevin Judice plays DiCE, pivoting from a $60M raise

    ENDPTS

    China NMPA approves Novartis’ Cosentyx in pediatric patients

    PHARMABIZ

    Novartis secures new approval in China for Cosentyx in pediatric psoriasis

    PRESS RELEASE

    Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis

    PHARMATIMES

    Novartis stakes another PhIII win for Cosentyx, goes deeper into pediatric

    ENDPTS

    Novartis Cosentyx receives FDA approval for treatment of children & adolescents

    PRESS RELEASE

    Cosentyx gains EU approval for new label extension

    PHARMATIMES

    Secukinumab in children with plaque psoriasis: Study unsuitable

    EUREKALERT

    Novartis reports positive results from Cosentyx trial

    CLINICALTRIALSARENA

    Novartis presents latest Phase III data reinforcing Cosentyx®

    NOVARTIS

    Novartis puts spokesceleb Cyndi Lauper in host chair for life-with-psoriasis

    FIERCEPHARMA

    AbbVie`s Skyrizi stands to gain as docs move away from older psoriasis meds

    FIERCEPHARMA

    Novartis Cosentyx® receives EU approval for first-line systemic treatment

    PRESS RELEASE

    Bimekizumab shows positive phase 3b results against Cosentyx

    HEALIO

    UCB touts another psoriasis win, this time over Cosentyx, as they look to break

    ENDPTS

    UCB`s investigational IL-17A and IL-17F inhibitor outclasses Novartis` Cosentyx

    PHARMAFILE

    Lilly`s Mirikizumab Superior to Cosentyx® (secukinumab)

    PRNEWSWIRE

    EMA committee recommends approval of Novartis Cosentyx

    PHARMABIZ

    Cosmo receives positive EMA CHMP Opinion recommending approval

    PRESS RELEASE

    Novartis`s Cosentyx (Secukinumab) Receives Supplemental Approval in US

    FDA

    Lilly`s Taltz outpaces Novartis` Cosentyx with 4th FDA approval

    FIERCE PHARMA

    Novartis wins expanded European OK for Cosentyx amid pursuit of $5 billion sales

    REUTERS

    EMA committee recommends approval of Novartis’ Cosentyx to treat radiographic

    PHARMABIZ

    Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial

    PRESS RELEASE

    Cosentyx, Entresto drive topline growth for Novartis in Q4

    PMLIVE

    Is mainstream DTC the go-to marketing path for biologics now?

    FIERCE PHARMA

    New Phase 3 Data Show SKYRIZI Superior to Cosentyx in Plaque Psoriasis

    PR NEWSWIRE

    AbbVie`s new hope Skyrizi bests Novartis` Cosentyx at clearing patients` skin

    FIERCE PHARMA

    Novartis, Cyndi Lauper shine a light on psoriasis challenges in the workplace

    FIERCE PHARMA

    Cosentyx hits endpoints in axSpA trial

    PHARMA TIMES

    Novartis Cosentyx shows encouraging results versus Humira

    PHARMABIZ

    Cosentyx ‘narrowly’ misses superiority VS Humira

    PHARMATIMES

    Novartis arthritis drug falls short in challenge to global bestseller

    REUTERS

    Novo drops oral GLP-1 analog to focus on next-gen Rybelsus

    FIERCE BIOTECH

    Cosentyx receives EU label update

    PHARMATIMES

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.